Recent Findings in Meningococcal Described by Researchers from GlaxoSmithKline plc (Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease In France: a Study of the National Health Insurance Database)

2021 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- Current study results on Meningococcal have been published. According to news reporting from Rueil-Malmaison, France, by NewsRx journalists, research stated, “Invasive meningococcal disease (IMD) is an uncommon but serious infectious disease. Its economic burden is known to be high but is poorly characterised.”

Financial support for this research came from GlaxoSmithKline.

The news correspondents obtained a quote from the research from GlaxoSmithKline plc, “The objective of this study was to determine costs, as captured in the healthcare claims database, incurred by all patients hospitalised for IMD in France over a 6-year period. This case-control study was performed using the French national public health insurance database (SNDS). Cases comprised all individuals hospitalised with acute IMD in France between 2012 and 2017 inclusive. For each case, three controls were identified, matched for age, gender and region of residence. All healthcare resource consumption by cases and controls during the follow-up period was documented. Costs were analysed for the index hospitalisation in cases, 1 year following the index date and then for 5 years following the index date. Costs were assigned from national tariffs. The analysis was performed from a societal perspective. IMD sequelae were identified from hospital discharge summaries. A total of 3532 cases and 10,590 controls were evaluated. The mean per capita cost of the index IMD hospitalisation was euro11,256, and increased with age and with the presence of sequelae. In the year following the index date, mean per capita direct medical costs were euro6564 in cases and euro2890 in controls. Annual costs were euro4254 in cases without sequelae, euro10,799 in cases with one sequela and euro20,096 in cases with more than one sequela. In the fifth year of follow-up, mean per capita costs were euro2646 in cases and euro1478 in controls. The excess cost in cases was principally due to the management of sequelae. Amputation, skin scarring and mental retardation generated per capita costs in excess of euro20,000 in the first year and in excess of euro10,000 for subsequent years.”

According to the news reporters, the research concluded: “The economic burden of IMD in France is high and, over the long-term, is driven by sequelae management.”

For more information on this research see: Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease In France: a Study of the National Health Insurance Database. Infectious Diseases and Therapy, 2021. Infectious Diseases and Therapy can be contacted at: Springer London Ltd, 236 Grays Inn Rd, 6TH Floor, London WC1X 8HL, England. (Springer - www.springer.com; Infectious Diseases and Therapy - http://www.springerlink.com/content/2193-6382/)

Our news journalists report that additional information may be obtained by contacting Celine Pribil, GlaxoSmithKline PLC, Rueil Malmaison, France. Additional authors for this research include Catherine Weil-Olivier, Muhamed-Kheir Taha, Corinne Emery, Stephane Bouee, Ekkehard Beck, Emmanuel Aris, Veronique Loncle-Provot and Gaelle Nachbaur.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s40121-021-00468-w. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)